Plain-English translation of NCT04992624 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This research is testing whether cannabinoid medications—either CBD (cannabidiol), THC (tetrahydrocannabinol), or a combination of both—can help reduce knee pain from arthritis. The study is designed to understand how these medications might work by targeting two different pain pathways: reducing inflammation in the knee itself, and changing how the brain processes pain signals. Researchers will track participants over time to see if the medication helps ease pain and improves quality of life.
Current treatments for knee arthritis don't work well for everyone, and many people experience side effects or limited relief. This trial explores whether this medication might offer a new option by addressing both the physical inflammation in the knee and the way pain signals travel through the brain.
You likely qualify if…
You likely don't qualify if…
You would take a daily dose of the medication (or placebo) for the study period and attend visits for pain assessments and MRI brain scans to measure how the treatment affects pain signals. Before each test visit, you'll need to stop taking certain pain relievers, avoid alcohol and nicotine for a few hours, and avoid intense exercise for 48 hours. The study involves detailed questionnaires about your pain, sensory testing, and brain imaging to see how the medication is working.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States